Clinical Trial Shows Benefits of Vinorelbine for Mesothelioma

Mesothelioma specialist Dr. Dean Fennell has strongly endorsed the use of vinorelbine as a second-line treatment for patients with relapsed disease. He was the lead investigator in a recent phase II clinical trial studying the efficacy of vinorelbine for patients whose pleural mesothelioma cancer had progressed after traditional platinum-based chemotherapy. Fennell, who is chair of thoracic and medical oncology at University of Leicester and University Hospitals in the United Kingdom, has based his belief on the multicenter trial involving 154 mesothelioma patients with relapsed disease. “Doctors should now feel more confident in offering vinorelbine to patients and expanding their choice of options past platinum-based chemotherapy,” Fennell told The Mesothelioma Center at Asbestos.com. “The study provides solid evidence to justify its use in a setting of unmet need.” Clinical Trial Results End Debate There currently is no second-line standard of care for pleural mesothelioma. Treatment can vary widely based upon the medical center and is often only palliative in nature. Vinorelbine is a different type of chemotherapy and classified as an antineoplastic agent. It comes with relatively low toxicity and is used for different cancers, mostly after recurrence. It is approved by the U.S. Food and Drug Administration for use with non-small cell lung cancer. Although it has been used for many years on an international level, there has bee...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Imagine a world in which physicians can confidently cure cancer. Two Bay Area life sciences companies are working together to make this vision a reality. Atara Biotherapeutics Inc., founded in 2012, is developing a pipeline of cell therapies to treat various types of cancer and autoimmune diseases. Bayer is licensing Atara’s cutting-edge cell therapies that t arget certain types of aggressive tumors including mesothelioma, pancreatic, ovarian and non-small-cell lung cancer. “With cancer therapies,…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Adding the drug ramucirumab to gemcitabine chemotherapy worked especially well in a recent clinical trial involving second-line treatment for patients with pleural mesothelioma. Ramucirumab, an immunotherapy drug also known by the brand name Cyramza, is a monoclonal antibody that works by targeting and restricting a protein that stimulates blood vessel growth within tumors. Impressive results in the phase II clinical trial moved the drug combination closer to filling the long-standing void for a second-line mesothelioma treatment. The Lancet Oncology recently published results of the study, which was conducted in ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conclusion: Combining EPD with HITOC can be performed in patients with either pleural mesothelioma or pleural metastases resulting in low perioperative morbidity and mortality as well as remarkable local tumor control.Respiration
Source: Respiration - Category: Respiratory Medicine Source Type: research
Dr. Maurizio D’Incalci already has seen Tumor Treating Fields working for patients with malignant pleural mesothelioma, and applauded the U.S. Food and Drug Administration’s approval of the treatment in 2019. He also knows the therapy is only scratching the surface of its vast potential and could be even more effective. He wants to help improve it. D’Incalci, a heralded biomedical science professor at Humanitas University in Milan, Italy, has begun a study exploring various drug combinations that could have a positive, synergistic effect with Tumor Treating Fields for mesothelioma. “There m...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
CONCLUSION: Novel immunotherapies are needed in cancer patients with resistance to or relapse after current immunotherapeutic drugs. Such new treatments may include targeted agents or monoclonal antibodies to overcome the immune-suppressive tumor microenvironment. The mode of combining the novel treatments, including vaccines, needs to be matched to the patient's immune status for achieving the maximum benefit. In this scenario, specific attention should be also paid nowadays to the immune intersection between COVID-19 and cancer.PMID:34301276 | DOI:10.1186/s13046-021-02023-4
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
ConclusionsOverall, our data suggest a 3-miRNAs signature as a non-invasive and accurate biomarker of lung AdCa. This approach could supplement the current screening approaches for early lung cancer diagnosis.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Researchers in the Netherlands are touting a novel breath test for mesothelioma patients to better predict response to the immunotherapy combination of nivolumab and ipilimumab that was approved recently for first-line treatment of the disease. They believe exhaled breath analysis using electronic technology – known as eNose – can differentiate between responders and nonresponders before treatment begins, saving many patients from unnecessary side effects. There currently are no biomarkers for mesothelioma that can accurately predict the effectiveness of these types of immunotherapy drugs, known as immune...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
We carefully read the article by Cantini et  al. [1]. This is an interesting study that evaluated the association between statin use and clinical outcomes of programmed cell death 1 (PD-1) use using a prospective database. If statins improve clinical outcomes in patients treated with PD-1 inhibitors, treatment strategies for malignant pleura l mesothelioma (MPM) and advanced non-small cell lung cancer (aNSCLC) will dramatically change. Furthermore, this study suggests that those who do not take statins may have a worse overall survival after the use of PD-1 inhibitors for both MPM and aNSCLC, highlighting the importan...
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research
We carefully read the article by Cantini et  al. [1]. This is an interesting study that evaluated the association between statin use and clinical outcomes of programmed cell death 1 (PD-1) use using a prospective database. If statins improve clinical outcomes in patients treated with PD-1 inhibitors, treatment strategies for malignant pleura l mesothelioma (MPM) and advanced non-small cell lung cancer (aNSCLC) will dramatically change. Furthermore, this study suggests that those who do not take statins may have a worse overall survival after the use of PD-1 inhibitors for both MPM and aNSCLC, highlighting the importan...
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research
The role of immunotherapy in cancer is now well-established, and therapeutic options such as checkpoint inhibitors are increasingly being approved in many cancers such as non-small cell lung cancer (NSCLC). Ma...
Source: BMC Pulmonary Medicine - Category: Respiratory Medicine Authors: Tags: Review Source Type: research
More News: Alimta | Asbestosis | Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Chemotherapy | Clinical Trials | Environmental Health | Food and Drug Administration (FDA) | Hospitals | Immunotherapy | Lung Cancer | Mesothelioma | Non-Small Cell Lung Cancer | Palliative | Respiratory Medicine | Study | Toxicology | UK Health